Smoking  >>  Semprana (dihydroergotamine oral inhalation)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Semprana (dihydroergotamine oral inhalation) / AbbVie
NCT01199965 / 2009-016732-12: Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers

Completed
1/2
47
Europe
MAP0004, IV DHE, D.H.E.45®
Allergan, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Healthy Subjects
04/10
04/10

Download Options